THIS AMENDED AND RESTATED LICENSE AGREEMENT is made as of April 3, 2003
and acknowledged and agreed to by:
Elan Pharmaceuticals, Inc., a Delaware corporation laving a place of business at 800 Gateway Blvd., San
Francisco, California 94080;
IE Oncology Company Limited, an international business company incorporated under the, laws of
Barbados and having its registered office at Bishop's Court Hill, St. Michael, Barbados; and
Inex Pharmaceuticals Corporation, a company duly amalgamated and validly existing under the laws of
British Columbia and having its principal place of business at 100 , 8900 Glenlyon Parkway, Burnaby,
British Columbia, Canada.
(1) Elan Corporation, plc., a public limited company incorporated under the laws of Ireland, and having
its registered office at Lincoln House, Lincoln Place, Dublin 2, Ireland;
(2) Elan Pharma International ltd. incorporated under the laws of Ireland, and -having its registered office
at WIL House, Shannon Business Park, Shannon, County Clare, Ireland; and
Inex International holdings Ltd., a Bermuda exempted limited liability company established under the
laws of Bermuda with an office at Cedar House, 41 Cedar Avenue, Hamilton, Bermuda.
Under that certain License Agreement dated April 27, 2001, EPIL (as defined below), .Elan Corp (as
defined below) and Elan (as defined below) licensed to IE Oncology (as defined below) certain
intellectual property owned, licensed or controlled by EPlf,, Elan Core or Elan (the "original License").
The Original License was issued in connection with the formation of IE Oncology by the Original Parties
(as defined below) for the purposes of development of certain oncology products.
On or about December 28, 2001, Elan acquired TLC (as defined below), including the intellectual
property formerly owned, licensed, or controlled by TLC and licensed to IE Oncology under the Original